Atlas Trials

Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients

Clinical trial NCT05383053 · COMPLETED

Trial details

NCT number
NCT05383053
Sponsor
Neurozen Inc.
Status
COMPLETED
Study type
OBSERVATIONAL
Alzheimer DiseaseMild Cognitive Impairment
Start date
2022-07-22
Primary completion
2022-08-10
Enrollment
227

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.